Production (Stage)
Acrivon Therapeutics, Inc.
ACRV
$1.17
$0.021.74%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.37% | -18.59% | -55.13% | -35.10% | -29.24% |
| Total Depreciation and Amortization | 38.84% | 103.36% | 88.72% | 76.74% | 79.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.00% | 18.70% | 0.71% | 27.59% | 75.53% |
| Change in Net Operating Assets | -0.87% | -49.22% | 17.42% | -23.01% | -786.51% |
| Cash from Operations | -14.35% | -40.38% | -76.66% | -52.58% | -50.42% |
| Capital Expenditure | 92.88% | 28.15% | -- | -22.32% | -3,160.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 189.15% | -29.73% | 1,021.37% | -551.96% | -28.73% |
| Cash from Investing | 228.44% | -29.82% | 956.13% | -555.29% | -37.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.73% | -100.00% | -100.00% | 18,371.77% | -- |
| Repurchase of Common Stock | -107.23% | 50.12% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -99.42% | 67.83% | -2,028.21% | 32,446.17% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.18% | -158.37% | 65.71% | 101.82% | -461.82% |